Abstract Purpose: Most tumors develop regions with hypoxic cells during growth, owing to permanent limitations in oxygen diffusion (chronic or diffusion-limited hypoxia) and/or transient limitations in blood perfusion (acute or fluctuating hypoxia).The aim of this study was to investigate the relative significance of chronic and acute hypoxia in the development of metastatic disease. Experimental Design: D-12 and R-18 human melanoma xenografts were used as models of human cancer. D-12 tumors metastasize to the lungs, whereas R-18 tumors develop lymph node metastases. Fraction of radiobiologically hypoxic cells (HF Rad ) was measured in individual primary tumors by using a radiobiological assay based on the paired survival curve method. Fraction of immunohistochemically hypoxic cells (HF Imm ) was assessed in the same tumors by using a pimonidazole-based immunohistochemical assay optimized with respect to achieving selective staining of chronically hypoxic cells. HF Imm and the difference between HF Rad and HF Imm , HF Rad À HF Imm , were verified to be adequate variables for fractionof chronically hypoxic cells and fractionof acutely hypoxic cells, respectively. Results: Chronic as well as acute hypoxia were found to promote spontaneous metastasis of D-12 and R-18 tumors. Acute hypoxia influenced metastasis to a greater extent than chronic hypoxia, partly because the fraction of acutely hypoxic cells was larger than the fraction of chronically hypoxic cells in most tumors and partly because acutely hypoxic cells showed a higher metastatic potential than chronically hypoxic cells. Conclusions: It may be beneficial to focus on fluctuating hypoxia rather than diffusion-limited hypoxia when searching for hypoxia-related prognostic variables and predictive assays.
Most experimental and human tumors are heterogeneous in oxygen tension (pO 2 ) and develop regions with hypoxic (pO 2 <10 mmHg) cells during growth (1) . Two main causes of tumor hypoxia have been recognized: permanent limitations in oxygen diffusion and transient limitations in blood perfusion (2) . Permanent limitations in oxygen diffusion result in development of hypoxic cells in regions far from blood vessels, typically adjacent to necrotic regions. These cells are termed chronically hypoxic and are in untreated tumors believed to remain hypoxic until they die because of lack of oxygen or nutrients. Chronically hypoxic cells have a lifetime within the range of 4 to 10 days in most experimental tumors (3) . Transient limitations in blood perfusion (i.e., transient cessations in microregional blood flow or temporal variations in microvessel RBC flux) result in development of hypoxic cells downstream of perfusion-impairing vessel abnormalities. These cells are termed acutely hypoxic and are believed to experience several short-term periods of hypoxia during their lifetime. The duration of these periods has been shown to range from less than a minute to several hours in experimental tumors (4) . This type of tumor hypoxia, often referred to as fluctuating hypoxia, should be distinguished from diffusion-limited hypoxia because cells in regions with fluctuating hypoxia may differ biologically from those in regions with diffusion-limited hypoxia (2 -4) .
A large number of methods have been introduced for assessing the fraction of hypoxic cells in tumors (5, 6) . Differing cell subpopulations are detected in different assays, implying that data derived from different assays may supplement one another (7) . Radiobiological assays measure the fraction of the clonogenic cells in tumors that are hypoxic (5 -7) . This hypoxic fraction is termed fraction of radiobiologically hypoxic cells and involves both chronically and acutely hypoxic cells. The fraction of radiobiologically hypoxic cells is considered to be of greater clinical significance than hypoxic fractions derived from nonradiobiological assays, as only clonogenic cells are of relevance for tumor growth and response to treatment (7, 8) . Immunohistochemical assays have been suggested to represent a useful supplement to radiobiological assays (9) . In these assays, antibodies to nitroimidazole-protein adducts are used to identify hypoxic cells in histologic preparations from tumors. Immunohistochemical assays preferentially detect tumor regions with diffusion-limited hypoxia as opposed to fluctuating hypoxia, particularly in paraformaldehyde-fixed tissue (10) but cannot be used to distinguish between clonogenic and nonclonogenic cells (5, 6, 9) .
Recent studies have suggested that hypoxia promotes malignant progression and metastatic spread of tumor tissue by selecting for aggressive cell phenotypes and by up-regulating the expression of genes involved in the metastatic process (11 -13) . Thus, clinical investigations involving several histologic types of cancer have shown that invasive growth, development of metastatic disease, or poor disease-free or overall survival rate is associated with the expression of hypoxia-inducible gene products or low pO 2 in the primary tumor (14 -17) . Studies of experimental tumors have indicated that tumors with high fractions of hypoxic cells metastasize more frequently than genetically equivalent control tumors with low fractions of hypoxic cells, whether high hypoxic fractions are ocurring naturally (18, 19) or are imposed by irradiating the tumor bed (20, 21) or by keeping the host mice in a low-oxygen atmosphere (22, 23) . These experimental and clinical studies, however, do not provide information on the nature of the hypoxia that promotes the development of metastatic cell phenotypes, as hypoxia was detected by the use of pO 2 electrodes or intrinsic and/or extrinsic hypoxia markers, methods that do not distinguish between fluctuating and diffusion-limited hypoxia (11 -23) .
Molecular mechanisms of hypoxia-induced metastasis have been studied in our laboratory by using D-12 and R-18 human melanoma xenografts as preclinical models of human cancer and pimonidazole as extrinsic hypoxia marker (18 -21) . D-12 tumors form spontaneous pulmonary metastases in athymic nude mice, and hypoxia was found to promote metastasis primarily by up-regulating the proangiogenic factor interleukin-8 (IL-8). R-18 xenografts develop spontaneous lymph node metastases, and hypoxia was found to promote metastasis primarily by up-regulating the invasive growth-promoting receptor urokinase-type plasminogen activator receptor (uPAR). In the work reported here, we used these tumor models to study the nature of the hypoxia that promotes metastasis. To do so, fraction of radiobiologically hypoxic cells (HF Rad ) and fraction of immunohistochemically hypoxic cells (HF Imm ) were measured in individual D-12 and R-18 primary tumors and related to the metastatic status of the host. HF Rad was measured by using an assay based on the paired survival curve method. This assay is particularly useful for accurate assessment of HF Rad in individual D-12 and R-18 tumors (24) . HF Imm was assessed by using a pimonidazolebased assay optimized with the purpose of achieving selective staining of chronically hypoxic cells (24) . HF Rad , HF Imm , and the difference between HF Rad and HF Imm (HF Rad À HF Imm ) were assumed to represent total fraction of hypoxic cells, fraction of chronically hypoxic cells, and fraction of acutely hypoxic cells, respectively. These assumptions have been verified to be valid for D-12 and R-18 tumors (24) . Therefore, fraction of chronically hypoxic cells is equated with HF Imm and fraction of acutely hypoxic cells is equated with HF Rad À HF Imm in the present communication. The experiments gave results suggesting that metastasis of D-12 and R-18 tumors is promoted by diffusion-limited as well as by fluctuating hypoxia, with fluctuating hypoxia being more important than diffusion-limited hypoxia in both tumor lines.
Materials and Methods
Mice and tumors. Adult (8-10 weeks of age) female BALB/c nu/nu mice, maintained as described elsewhere (25) , were used as host animals for xenografted tumors. Primary tumors were initiated from D-12 or R-18 monolayer cell cultures (25 Tumor irradiation. A Siemens (Erlangen, Germany) Stabilipan X-ray unit, operated at 220 kV, 19 to 20 mA, and with 0.5-mm copper filtration, was used for irradiation. The tumors were irradiated at a dose rate of 5.1 Gy/min, using a radiation field of 15 Â 15 mm (24) . The mice were anesthetized with ketamine (33 mg/kg) and azaperone (25 mg/kg), and the body core temperature of the mice was kept at 37jC to 38jC during irradiation by using a heating lamp. The anesthesia did not alter the total blood perfusion or the extent of transient blood perfusion in the tumors significantly, as verified in separate experiments by using the 86 Rb uptake method and the double-fluorescent staining technique, respectively. Hypoxic tumors were obtained by occluding the bloodsupply with a clamp 5 min before irradiation (24) .
Cell survival assay. Tumor cell survival was measured in vitro, using a plastic surface colony assay (27) . A standardized mechanical and enzymatic procedure was used to prepare single-cell suspensions (28) . Briefly, the tumors were minced in cold HBSS before enzymatic treatment at 37jC for 2 h. The enzyme solution consisted of 0. Radiobiological hypoxia. Fraction of radiobiologically hypoxic cells was determined for individual tumors by using a procedure based on the paired survival curve method (24) . The tumors were irradiated with 10 Gy under unclamped conditions, and fraction of surviving cells [SF 10 (unclamped)] was determined for each tumor as described above. Fraction of radiobiologically hypoxic cells was then calculated as SF 10 (unclamped) / SF 10 (clamped), where SF 10 (clamped) represents the mean cell surviving fraction of 10 tumors irradiated with 10 Gy under clamped conditions. The determination of the fraction of radiobiologically hypoxic cells of individual D-12 and R-18 tumors from measurements of SF 10 has been justified previously (24) .
Immunohistochemical hypoxia. Fraction of chronically hypoxic cells was determined for individual tumors by using a peroxidase-based immunohistochemical assay, optimized with the purpose of staining chronically hypoxic cells adequately without staining normoxic or acutely hypoxic cells significantly. The assay and a critical experimental evaluation of the assay have been reported in detail elsewhere (24) . Metastasis. The primary tumors were resected at predetermined times after initiation. The host mice were then examined daily for clinical signs of metastases (listlessness, weight loss, or hunched posture). They were euthanized 3 months after the primary tumor resection or when moribund. Mice having borne D-12 primary tumors were examined for pulmonary metastases (i.e., the lungs were fixed in Bouin's solution for 24 h and inspected for macroscopic metastases by stereomicroscopy; ref. 18 ). Mice having borne R-18 primary tumors were examined for external lymph node metastases in the interscapular, submandibular, axillary, and inguinal regions and internal lymph node metastases in the abdomen and mediastinum (19) . Metastases were always found in moribund mice. The presence of metastases was confirmed by histologic examinations. Mice were scored to be metastasis negative if pulmonary (D-12) or lymph node (R-18) metastases could not be detected by autopsy 3 months after the primary tumor was resected. Further details of the assays have been reported elsewhere (18 -21, 26) .
Statistical analysis. Experimental data are presented as arithmetic mean F SE unless otherwise stated. The Pearson product moment correlation test was used to search for correlations between variables. Statistical comparisons of data sets were carried out by using the Student's t test (single comparisons) or by one-way ANOVA (multiple comparisons) when the data sets complied with the conditions of normality and equal variance. Under other conditions, comparisons were carried out by nonparametric analysis using the Mann-Whitney rank-sum test (single comparisons) or the Kruskal-Wallis one-way ANOVA on ranks (multiple comparisons). The Bonferroni method (parametric tests) or the Dunett method (nonparametric tests) was used to identify data sets that differed from the control data in multiple comparisons. The Kolmogorov-Smirnov method was used to test for normality. Errors inherent in intermediate analyses were propagated through to the final analyses. Probability values of P < 0.05, determined from two-sided tests, were considered significant. The statistical analysis was carried out by using SigmaStat statistical software (Jandel Scientific GmbH, Erkrath, Germany).
Results
Fifty mice with D-12 tumors and 50 mice with R-18 tumors were included in the metastasis experiments. When having reached a volume of 400 to 500 mm 3 , the tumors were irradiated with 10 Gy, resected, and cut into f1-mm-thick slices. One half of each tumor (every second slice) was processed for measurement of SF 10 (unclamped) and fraction of radiobiologically hypoxic cells, whereas the other half was processed for assessment of fraction of chronically hypoxic cells. The host mice were examined for development of macroscopic metastases for the next 3 months. SF 10 (unclamped) differed by a factor of f7.5, from 1.57 Â 10 À3 to 1.17 Â 10 À2 , among the 50 D-12 tumors (Fig. 1A) , and by a factor of f4.3, from 2.46 Â 10 À2 to 1.05 Â 10 À1 , among the 50 R-18 tumors (Fig. 1B) . In comparison, SF 10 (clamped) of 10 D-12 control tumors and SF 15 (clamped) of 10 D-12 control tumors differed by factors of f1.7 and f2.0, respectively (Fig. 1A) , and SF 10 (clamped) of 10 R-18 control tumors and SF 15 (clamped) of 10 R-18 control tumors differed by factors of f1.8 and f1.9, respectively (Fig. 1B) . The geometric means of SF 10 (unclamped), SF 10 (clamped), and SF 15 (clamped), indicated at Fig. 1 (horizontal 10 (unclamped) among the 50 D-12 tumors and the differences in SF 10 (unclamped) among the 50 R-18 tumors thus primarily reflected differences in fraction of radiobiologically hypoxic cells and not experimental uncertainty. The fraction of radiobiologically hypoxic cells of the 50 D-12 tumors differed from 9% to 67%, with a geometric mean of 26% and an arithmetic mean of 29%, and the fraction of radiobiologically hypoxic cells of the 50 R-18 tumors differed from 21% to 90%, with a geometric mean of 50% and an arithmetic mean of 53%.
The tumors of both lines showed highly heterogeneous staining for pimonidazole. The staining pattern was consistent with staining of chronically hypoxic cells without staining of normoxic or acutely hypoxic cells (Fig. 2) . The D-12 tumors had developed regions with large necroses, regions composed of tumor chords and small necroses, and large regions without necrosis ( Fig. 2A) . The necrotic regions were always encompassed by a rim of pimonidazole-positive cells, two to four cell layers thick. The periphery of the tumor chords also stained (Fig. 2B) . Foci of tumor cells staining positive for pimonidazole were seen throughout the tissue. These pimonidazole-positive foci differed substantially in size and shape, and a few necrotic or necrotizing cells were seen in the middle of some of the largest foci. In tumors of both lines, the boundary line between stained and unstained cells was sharp (i.e., the cells showed either intense brown staining or no staining). Positive staining of cells adjacent to identifiable blood vessels or cells in the center of tumor chords could not be detected in any tumor.
The fraction of chronically hypoxic cells of the 50 D-12 tumors ranged from 5% to 28% with a mean value of 16.1%, and the fraction of chronically hypoxic cells of the 50 R-18 tumors ranged from 4% to 19% with a mean value of 9.5%. There was a weak positive correlation between fraction of radiobiologically hypoxic cells and fraction of chronically hypoxic cells, for both the D-12 tumors (correlation coefficient, 0.41; P = 0.0030; Fig. 3A ) and the R-18 tumors (correlation coefficient, 0.34; P = 0.016; Fig. 3B ). However, fraction of radiobiologically hypoxic cells was higher than fraction of chronically hypoxic cells in all individual tumors ( Fig. 3A and B) . Fraction of acutely hypoxic cells differed from 1% to 53% with a mean value of 12.6% for the D-12 tumors and from 10% to 82% with a mean value of 43.8% for the R-18 tumors. There was no correlation between fraction of acutely hypoxic cells and fraction of chronically hypoxic cells (P > 0.05 for both D-12 and R-18 tumors; Fig. 4 ). Mean fraction of acutely hypoxic cells was lower than mean fraction of chronically hypoxic cells for the D-12 tumors (P = 0.0012) and higher than mean fraction of chronically hypoxic cells for the R-18 tumors (P < 0.000001). Only 13 of the 50 D-12 tumors showed a fraction of acutely hypoxic cells that was higher than the fraction of chronically hypoxic cells (Fig. 4A) , whereas the fraction of acutely hypoxic cells was higher than the fraction of chronically hypoxic cells in 49 of the 50 R-18 tumors (Fig. 4B) .
Twenty-seven of the 50 mice bearing D-12 tumors developed pulmonary metastases, whereas 23 mice did not. Extrapulmonary metastases were not observed in any mouse. The tumors that caused metastases showed f1.7-fold higher fraction of radiobiologically hypoxic cells than those that did not metastasize (P < 0.000001; Fig. 5A ). Fraction of chronically hypoxic cells was f1.3-fold higher in the tumors that metastasized than in those that did not (P = 0.015; Fig. 5B ), and fraction of acutely hypoxic cells was f2.5-fold higher in the metastatic than in the nonmetastatic tumors (P = 0.0024; Fig. 5C ). Moreover, 26 of the 50 mice bearing R-18 tumors developed lymph node metastases, whereas 24 mice did not. Extralymphatic metastases were not detected in any mouse. The tumors that metastasized showed f1.5-fold higher fraction of radiobiologically hypoxic cells than those that did not metastasize (P < 0.000001; Fig. 6A ). Fraction of chronically hypoxic cells was f1.4-fold higher in the metastatic than in the nonmetastatic tumors (P = 0.0078; Fig. 6B ), and the metastatic tumors showed f1.6-fold higher fraction of acutely hypoxic cells than the nonmetastatic tumors (P < 0.000001; Fig. 6C ). Thus, metastatic and nonmetastatic tumors of both lines differed significantly in fraction of radiobiologically hypoxic cells, fraction of chronically hypoxic cells, and fraction of acutely hypoxic cells (Figs. 5 and 6 ).
In the D-12 line, the difference between metastatic and nonmetastatic tumors was 14.3% for mean fraction of radiobiologically hypoxic cells, 3.8% for mean fraction of chronically hypoxic cells, and 10.5% for mean fraction of acutely hypoxic cells [i.e., the difference was f3.8-fold larger for fraction of radiobiologically hypoxic cells than for fraction of chronically hypoxic cells (P = 0.0042) and f2.8-fold larger for fraction of acutely hypoxic cells than for fraction of chronically hypoxic cells (P = 0.047); Fig. 5 ]. In the R-18 line, the difference between the tumors that metastasized and those that did not was 22.3% for mean fraction of radiobiologically hypoxic cells, 3.0% for mean fraction of chronically hypoxic cells, and 19.3% for mean fraction of acutely hypoxic cells [i.e., the difference was f7.4-fold larger for fraction of radiobiologically hypoxic cells than for fraction of chronically hypoxic cells (P = 0.00014) and f6.4-fold larger for fraction of acutely hypoxic cells than for fraction of chronically hypoxic cells (P = 0.0020); Fig. 6 ]. Thus, fraction of radiobiologically hypoxic cells and fraction of acutely hypoxic cells discriminated significantly better between metastatic and nonmetastatic tumors than did fraction of chronically hypoxic cells. Three conditions indicate that the extent of chronic tumor hypoxia was overestimated and the extent of acute tumor hypoxia was underestimated in our study. First, the clonogenicity of chronically hypoxic cells may be lower than the clonogenicity of normoxic and acutely hypoxic cells (7, 30) . Second, pimonidazole staining occurs at pO 2 <7.5 to 10.0 mmHg (24) , whereas 50% radiosensitization occurs at pO 2 = 3.0 to 7.5 mmHg (5, 31). Third, chronically hypoxic cells may be more sensitive to radiation than acutely hypoxic cells (32) . Consequently, fraction of chronically hypoxic cells, defined here as being equal to HF Imm , represents the upper limit of the fraction of the clonogenic tumor cells that are chronically hypoxic, and fraction of acutely hypoxic cells, defined here as being equal to HF Rad À HF Imm , represents the lower limit of the fraction of the clonogenic tumor cells that are acutely hypoxic.
The present experiments suggest that the ratio between fraction of acutely hypoxic cells and fraction of chronically hypoxic cells may differ substantially among tumor lines and among individual tumors of the same line. Thus, mean fraction of acutely hypoxic cells and mean fraction of chronically hypoxic cells were 12.6% and 16.1%, respectively, for the D-12 (24) . Taken together, these data suggest that the fraction of acutely hypoxic cells often is larger than the fraction of chronically hypoxic cells in human melanoma xenografts. Apparently, tumors of other histologies may show hypoxia patterns diverging from those of melanomas. However, Durand and LePard (33) estimated the extent of acute hypoxia in SCCVII murine tumors by using a dual-staining technique, and they concluded that the majority of the 15% to 20% radiobiologically hypoxic cells were acutely hypoxic. A similar conclusion was reached by Kimura et al. (34) who estimated the extent of acute hypoxia in R3230Ac rat tumors grown in dorsal flap window chambers from measurements of fluctuations in RBC flux and pO 2 . Recently, oxygen electrodes have been used to study fluctuations in pO 2 in a large number of tumors, and it has been shown that tissue pO 2 may fluctuate around threshold values in the range 3 to 10 mmHg in large regions of rodent tumors (34 -37), human tumor xenografts (38 -40) , and spontaneous canine tumors (41) .
Experimental studies of correlations between tumor hypoxia and metastasis require tumor models that make it possible to distinguish clearly between metastatic and nonmetastatic primary tumors, as is the case for the D-12 and R-18 melanomas. Separate experiments with the D-12 melanoma have shown that (a) macroscopic metastases and/or micrometastatic disease are present in the lungs of some mice at the time of primary tumor resection and (b) mice appearing healthy 3 months after the resection show lungs without histologic signs of metastatic disease, whereas mice showing clinical signs of metastatic disease at that time have lungs with macroscopic metastases only. Moreover, studies involving D-12 and R-18 tumors have shown that mice appearing healthy 3 months after the primary tumor is resected also are free from metastases 3 months later, as revealed by detailed histologic examinations of lungs and lymph nodes (18 -21) . Consequently, it is highly unlikely that micrometastatic disease was present in mice scored as metastasis-negative in our study.
The work reported here suggests that diffusion-limited as well as fluctuating hypoxia in the primary tumor promote metastasis of D-12 and R-18 tumors. This suggestion is based on the observations that there was no correlation between fraction of chronically hypoxic cells and fraction of acutely hypoxic cells and that metastasis was positively correlated to fraction of chronically hypoxic cells as well as fraction of acutely hypoxic cells. Furthermore, because fraction of acutely hypoxic cells discriminated better between metastatic and nonmetastatic tumors than did fraction of chronically hypoxic cells, fluctuating hypoxia probably influenced metastasis to a greater extent than diffusion-limited hypoxia. In R-18 tumors, this conclusion is consistent with the observation that the fraction of acutely hypoxic cells generally was substantially larger than the fraction of chronically hypoxic cells. However, this conclusion is valid also for the D-12 line where the fraction of acutely hypoxic cells was smaller than the fraction of chronically hypoxic cells in the majority of the tumors, suggesting that acutely hypoxic cells have a higher metastatic potential than chronically hypoxic cells.
Differences in metastatic potential between acutely and chronically hypoxic cells may be related to their localization within tumors. Chronically hypoxic cells are in most tumors located at some distance from functional blood vessels and lymphatics and often adjacent to necrotic regions (42) . The pimonidazole staining pattern observed here suggests that this is the case also for D-12 and R-18 tumors. Acutely hypoxic cells, on the other hand, can be located adjacent to functional blood vessels and in the tumor periphery close to functional lymphatics (42) . In addition to having easier access to functional vessels, acutely hypoxic cells may have higher energy status than chronically hypoxic cells (3, 7, 30, 32) It has been suggested that tumor hypoxia may promote metastatic dissemination also by selecting for hypoxia-resistant, highly metastatic cell variants (43) . This is not a likely mechanism for hypoxia-promoted metastasis in D-12 and R-18 tumors. Studies in our laboratory have shown that longterm culturing of D-12 and R-18 cells under chronic or cyclic (acute) hypoxia in vitro does not induce or select for cell variants with enhanced metastatic potential.
Cairns et al. (22) have also carried out experimental studies, suggesting that acutely hypoxic cells have a higher metastatic potential than chronically hypoxic cells. They induced chronic or acute hypoxia in KHT tumors by exposing tumor-bearing mice to a low-oxygen atmosphere of 5% to 7% O 2 during tumor growth and observed that mice exposed to acute hypoxia developed a larger number of microscopic lung metastases than mice exposed to chronic hypoxia. However, there is a fundamental difference between this study and the study reported here. For the KHT tumors, all tumor cells were exposed to chronic or acute hypoxia independent of their nutritional status and localization within the tumors (22) . In the present work with D-12 and R-18 tumors, effects of naturally occurring acute and chronic hypoxia on metastatic dissemination and growth were studied.
The observation that metastatic spread may be promoted by chronic as well as acute tumor hypoxia has significant clinical implications. It has been suggested that induction of tumor hypoxia may be a useful strategy for enhancing the efficacy of some therapeutic agents [e.g., hyperthermia (44) and hypoxic cell cytotoxins (45) ]. One consequence of our study is that treatment strategies involving deliberate tumor hypoxification should be avoided. Moreover, some treatment strategies may increase the fraction of hypoxic cells in tumors by impairing tumor blood supply [e.g., antiangiogenic treatment (46), treatment with vascular disrupting agents (47) , and some forms of photodynamic therapy (48) ]. The possibility that such treatments may cause tumor hypoxia and hence promote metastasis should be studied in detail before large-scale clinical investigations are initiated.
In summary, tumors may contain chronically hypoxic cells caused by permanent limitations in oxygen diffusion and Hypoxia may promote metastasis by up-regulating the expression of metastasis-promoting gene products. The preclinical study reported here suggests that fluctuating hypoxia may represent a more serious problem to cancer patients than diffusion-limited hypoxia, partly because the fraction of acutely hypoxic cells may be larger than the fraction of chronically hypoxic cells in most tumors and partly because acutely hypoxic cells may have a higher metastatic potential than chronically hypoxic cells. Consequently, it may be beneficial to focus on fluctuating hypoxia rather than diffusion-limited hypoxia when searching for hypoxia-related prognostic variables and predictive assays of treatment outcome.
